Rajiv De Silva
Rajiv De Silva is President, Chief Executive Officer and a Director of Endo International plc. Prior to joining Endo in March 2013, Mr. De Silva served as the President of Valeant Pharmaceuticals International, Inc. from October 2010 to January 2013 and served as its Chief Operating Officer, Specialty Pharmaceuticals from January 2009 until January 2013. At Valeant, he was responsible for all specialty pharmaceutical operations, including sales and marketing, research and development, manufacturing and business development. Prior to joining Valeant, Mr. De Silva held various leadership positions with Novartis. He served as President of Novartis Vaccines USA and Head, Vaccines of the Americas at Novartis. During this time, he played a key leadership role at Novartis’ Vaccines & Diagnostics Division. Mr. De Silva also served as President of Novartis Pharmaceuticals Canada. He originally joined Novartis as Global Head of Strategic Planning for Novartis Pharma AG in Basel, Switzerland. Prior to his time at Novartis, Mr. De Silva was a Principal at McKinsey & Company and served as a member of the leadership group of its Pharmaceuticals and Medical Products Practice. He has broad international experience, having managed businesses in the United States, Europe, Canada, Latin America, Asia, South Africa and Australia/New Zealand. Mr. De Silva was a Director of AMAG Pharmaceuticals, Inc. and is currently a Member of the Board of Trustees at Kent Place School in Summit, NJ. He holds a Bachelor of Science in Engineering, Honors from Princeton University, a Master of Science from Stanford University and a Master of Business Administration with Distinction from the Wharton School at the University of Pennsylvania.
Paul V. Campanelli
Paul V. Campanelli was appointed President, Par Pharmaceutical, effective September 28, 2015. In this role, he leads Endo’s fully integrated U.S. Generics business. Prior to joining Endo, Mr. Campanelli served as Chief Executive Officer of Par Pharmaceutical Companies, Inc. following the company’s September 2012 acquisition by TPG. Under his leadership, the company significantly increased total revenue, acquired Michigan-based JHP Pharmaceuticals, established a business office in London to serve as Par’s entry point into the European generics market and most recently completed its acquisition of an active pharmaceutical ingredients (API) facility located in Chennai, India. Prior to the TPG acquisition, Mr. Campanelli served as chief operating officer and president of Par Pharmaceutical, Inc., the company’s generics division, from 2011 to 2012. Earlier in his tenure at Par, Mr. Campanelli held roles of increasing responsibility, including Senior Vice President, Business Development & Licensing; Executive Vice President and President of Par Pharmaceutical, Inc.; and was named a Corporate Officer by Par’s board of directors. He also served on the board of directors of Sky Growth Holdings Corporation. Prior to joining Par, Mr. Campanelli served as vice president, Business Development at Dr. Reddy’s Laboratories Ltd. where he was employed from 1992-2001. He earned his Bachelor of Science degree from Springfield College.
Susan Hall, Ph.D.
Susan Hall, Ph.D. was appointed as Executive Vice President, Chief Scientific Officer and Global Head of Research & Development and Quality in March 2014. Dr. Hall is based in Dublin, Ireland at Endo’s global corporate headquarters. Prior to joining Endo, Dr. Hall served as Senior Vice President and Global Head of Research and Development at Valeant Pharmaceuticals International, Inc. In this position, she led the company’s product pipeline and life cycle management activities and also had responsibility for quality compliance. In addition, Dr. Hall has also held various leadership roles in research & development at GlaxoSmithKline including clinical pharmacology, project management, medical affairs, and regulatory affairs. Dr. Hall holds a B.S. degree in pharmacology from the University of Leeds (U.K.) and a Ph.D. in Pharmacokinetics from the Department of Pharmacy, University of Manchester (U.K.).
Brian Lortie is President, U.S. Branded Pharmaceuticals. In this role he leads the fully integrated Endo U.S. Pharmaceuticals business with responsibility for all strategic, commercial, and operational functions including sales and marketing, strategy and portfolio development, commercial operations, managed markets, supply chain, and quality. He joined Endo in 2009 from GlaxoSmithKline, having served in a number of executive roles in the U.S. and internationally, including Vice President, External Ventures; Vice President of Marketing, U.S.; Vice President and Global Head, HPV Vaccine Franchise; and Managing Director/General Manager, Ireland. Mr. Lortie holds a Bachelor of Arts degree with honors in Biology and Psychology from Boston University and studied at the Villanova University Graduate School of Business.
Matthew J. Maletta
Matthew J. Maletta was appointed Executive Vice President, Chief Legal Officer effective May 4, 2015. He brings to his role nearly two decades of legal experience in the specialty pharmaceutical industry and with private law firms, including extensive experience in M&A, corporate, securities, finance, commercial and employment law. Prior to joining Endo, Mr. Maletta served as Vice President, Associate General Counsel and Corporate Secretary of Allergan, Inc. In this position, he served as an advisor to the CEO and Board of Directors and supervised several large M&A transactions and takeover defense activities, including Allergan’s acquisition of Inamed and Actavis’ acquisition of Allergan. Mr. Maletta first joined Allergan in 2002 as Corporate Counsel and Assistant Secretary and during his tenure, held various roles of increased responsibility. He had a key role negotiating Allergan’s Corporate Integrity Agreement with the Department of Justice, served as the lead commercial attorney for the Allergan medical businesses and served as Interim Head of Human Resources. Prior to joining Allergan, Mr. Maletta was in private practice, focusing on general corporate matters, finance, governance, securities and transactions. He holds a B.A. degree in political science from the University of Minnesota, summa cum laude, and a J.D. degree, cum laude, from the University of Minnesota Law School. From 2012 – 2015, Mr. Maletta served as a member of the Board of Directors of United Cerebral Palsy – Orange County (UCP) and co-chaired UCP’s annual “Life Without Limits” galas in 2012, 2013 and 2015.
Dan A. Rudio
Daniel A. Rudio was appointed Vice President, Controller and Chief Accounting Officer effective April 1, 2011. Mr. Rudio joined Endo in November 2006 as Financial Reporting Manager and has held various positions of increasing responsibility. Prior to joining the Company, Mr. Rudio was a finance manager at Rohm and Haas Company where he worked for four years in a variety of accounting and finance positions of increasing responsibility. Mr. Rudio began his career in public accounting at Ernst & Young LLP where he worked from July 1995 to November 2002. Mr. Rudio is a licensed certified public accountant in the Commonwealth of Pennsylvania and holds Bachelors of Science degrees in both accounting and finance from Rutgers University.
Suketu “Suky” Upadhyay, Executive Vice President and Chief Financial Officer, joined Endo in September 2013. Prior to joining Endo, since 2010, Mr. Upadhyay served as Interim Chief Financial Officer as well as Senior Vice President of Finance and Corporate Controller of Becton, Dickinson & Co (BD). In addition to other executive finance roles at BD, from 2007 to 2010, he served in various finance leadership roles at AstraZeneca and Johnson & Johnson. Mr. Upadhyay spent the early part of his career in public accounting with KPMG and received his CPA in May 1996. He received a Bachelor of Science in Finance from Albright College and received a Master of Business Administration from The Fuqua School of Business at Duke University.
Mark Beaudet joined Endo in March 2014 as President of Paladin Labs Inc., a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for Canadian and emerging markets. He is a co-founder of Paladin and served as a director as well as the company’s interim President and CEO since 2011. Prior to that, Mr. Beaudet was Vice President of Sales and Marketing for Paladin from 1996 to 2011. Prior to his work with Paladin, he held marketing management positions at Procter & Gamble Canada and Pizza Hut Canada. Mr. Beaudet also led the pharmaceutical division campaigns for Centraide of Greater Montreal from 2007 through 2013. In 2003, Mr. Beaudet was a co-recipient of the Ernst and Young Entrepreneur of the Year award in the Quebec Life Sciences Sector. He holds a B.Comm in Marketing and Entrepreneurship with Great Distinction from McGill University and is a member of the board of directors of the McGill University Health Center Foundation, the Loyola High School Foundation and Rx&D - Canada’s Research Based Pharmaceutical Industry Association.
Robert J. Cobuzzi Jr., Ph. D.
Robert J. Cobuzzi Jr. is President, Endo Ventures Limited based in Dublin, Ireland. Dr. Cobuzzi joined Endo in 2005 and has held the positions of Senior Vice President, Corporate Development and most recently, Senior Vice President, R&D Strategy and Operations. Before joining Endo, he held management positions in clinical development and licensing at Adolor Corporation. Prior to Adolor, Dr. Cobuzzi gained extensive experience in global regulatory affairs and biologics at Centocor/Johnson & Johnson, and in clinical development at AstraMerck in the areas of thrombosis and hypertension. Dr. Cobuzzi received his Ph.D. in molecular and cellular biochemistry from Loyola University Chicago, and a Bachelor of Arts degree with majors in biochemistry and art history from Colby College. He completed a post-doctoral fellowship in the Department of Experimental Therapeutics at Roswell Park Cancer Institute. He previously served as a member of the U.S. Department of Commerce and the Office of the U.S. Trade Representative’s Industry Trade Advisory Committee on Chemicals, Pharmaceuticals, Health/Science Products and Services. He currently serves as a member of Sunstone Capital’s Business Development Advisory Board, and as a member of the Science and Technology Advisory Board of the Children’s Hospital of Philadelphia.
Larry Cunningham, Executive Vice President, Human Resources, joined Endo in May 2008. In this role he leads all aspects of human resources in enabling the development and growth of Endo. Prior to joining Endo, Mr. Cunningham led Johnson & Johnson’s global recruiting and talent acquisition organization. Mr. Cunningham also has extensive business-based human resources leadership experience. He was Vice President, Human Resources, for DePuy, Inc., a wholly owned subsidiary of Johnson & Johnson, which he joined following the acquisition of Centocor, where he was Vice President, Human Resources. Prior to joining Centocor, Mr. Cunningham gained extensive domestic and international experience in human resources management and organization development at Rhone-Poulenc Rorer (now Sanofi-Aventis) and Corning Clinical Laboratories (now Quest Diagnostics). Mr. Cunningham holds a B.A. in Labor Studies from the Pennsylvania State University and a Master of Science in Business Administration from Temple University.
Keri P. Mattox
Keri P. Mattox joined Endo as Senior Vice President, Investor Relations & Corporate Affairs in February 2015. In her role, Keri is responsible for the development and implementation of the company’s comprehensive and strategic IR and corporate communications platform as well as Government Affairs efforts. Ms. Mattox brings more than 15 years of experience in strategic life sciences communications, investor relations and journalism to Endo. Most recently, she was Senior Vice President, Investor Relations and Corporate Communications for Auxilium Pharmaceuticals, Inc. Prior to Auxilium, she Executive Vice President at Pure Communications, a life sciences communications firm where she managed all aspects of communications and IR strategy for publicly-traded and private company clients across the biotech and pharmaceuticals spectrum. Her clients have been featured on CNBC and in the Wall Street Journal, New York Times and Forbes. Prior to Pure, Ms. Mattox served as an independent communications consultant, the Director of Corporate Communications and Investor Relations for both NABI Biopharmaceuticals and DOV Pharmaceuticals and the Director of Science Marketing and Economic Development for the University of Pennsylvania. Previously, she was an Account Director at FitzGerald Communications in Boston and then Washington, D.C., where she headed up the agency’s life sciences initiatives.
Ms. Mattox began her career as a news and business reporter for Hearst Newspapers in New York and the Capital News Service in Washington, D.C. She holds a BA in Political Science from Boston University and an MA in Journalism from the University of Maryland.
Norbert Oppitz joined Endo in October 2014 as Regional President, Latin America, Africa and Export Markets. In this role, he is responsible for the expansion of Endo’s Latin American and emerging markets business leveraging the Company’s existing portfolio of assets as well as advancing new business opportunities. Prior to joining Endo, Mr. Oppitz served as Senior Vice President, Latin America for Takeda Pharmaceuticals, a role he held since 2010 when he joined Nycomed, which was subsequently acquired by Takeda. During his tenure, Norbert led a fully-integrated multi-national region including Mexico, Venezuela, and Argentina. Prior to Takeda/Nycomed, Norbert held leadership positions of increasing scope and complexity at F. Hoffman-La Roche S.A. and Sanofi SA. Mr. Oppitz has over 26 years of emerging market management experience in the pharmaceutical industry and holds a Business Administration degree from Fachhochschule Rheinland Pfalz, Mainz, Germany.
Bob Rush was appointed Senior Vice President, Corporate Initiatives on October 12, 2015. In this position, he plays a significant role in the integration of the Par Pharmaceutical and Qualitest businesses, as well as leads other critical enterprise initiatives that support the growth aspirations of Endo. He most recently served as interim General Manager, U.S. Generics. Mr. Rush joined Endo in January 2014 as Senior Vice President Finance where he was responsible for financial planning, analysis and performance reporting across the organization. During his tenure at Endo, he has worked closely with the Endo leadership team and the Qualitest business leading and driving several key growth initiatives. Mr. Rush brings more than 20 years of healthcare experience to the organization. Prior to joining Endo, he held various U.S. and International financial leadership roles at Becton Dickinson, Novartis and AstraZeneca. Mr. Rush received his Bachelors of Science in Accounting from the University of Delaware and Masters of Business Administration from Widener University.
Jon Smollen, Executive Vice President and Chief Compliance Officer, joined Endo in August 2011. In this role, he is responsible for the strategic direction and operations of Endo’s corporate compliance program. Mr. Smollen previously was Vice President and Chief Compliance Officer for Siemens Healthcare USA with responsibility for its laboratory diagnostic and diagnostic imaging businesses in the U.S. Prior to Siemens, Mr. Smollen held a number of leadership positions at Wyeth including Vice President, Commercial Excellence and Compliance and Chief Privacy Officer and established several global programs to strategically address existing and emerging industry requirements. Prior to Wyeth, Mr. Smollen was an Attorney Advisor to Federal Trade Commissioner Thomas B. Leary and was in private practice in Washington, D.C. He also served as a federal judicial clerk. He holds a B.A. from Georgetown University, an M.A. in International Relations from Columbia University and a J.D. from the University of Virginia School of Law.
Hemanth J. Varghese, Ph.D.
Hemanth J. Varghese, Ph.D. joined Endo in April 2014 as Executive Vice President Corporate Development and Strategy to lead the company’s global acquisitions and integration efforts. Dr. Varghese brings to Endo a successful track record in corporate development and general management in specialty pharmaceuticals, most recently serving as the Senior Vice President and General Manager of Vision Care for Bausch & Lomb, a division of Valeant Pharmaceuticals. During his tenure with Valeant, Dr. Varghese held various senior leadership roles including Senior Vice President of Corporate Development and General Manager of Valeant's Neurology & Other business unit. Over his career he has completed more than 40 corporate transactions, leading corporate development and integration initiatives including public/private acquisitions, investments, partnerships, licenses and divestitures. Prior to joining Valeant, Dr. Varghese served in corporate development and operations leadership roles at Biovail Corporation, JovInvestment Management Inc., and Robarts Research Institute. He obtained his BSc degree with honors in Biophysics and PhD in Medical Biophysics from the University of Western Ontario and holds the Charted Financial Analyst ® designation.
Julie B. Yankovich
Julie Yankovich serves as Senior Vice President of Employee Communications and Business Operations at Endo. Ms. Yankovich joined Endo in March 2013. In her role, she is responsible for all internal communications at Endo as well as Business Operations matters related to the Corporate Office of the CEO. In this capacity she has managed multiple strategic activities including the formulation and communications of the company vision and mission, implementing employee engagement surveys, leading the integration of several acquisitions, managing the establishment of the new Corporate headquarters in Ireland, and providing oversight and mentorship to the administrative staff at the headquarters. Prior to her tenure at Endo, Ms. Yankovich was the Director of Business Operations at Valeant Pharmaceuticals International Inc. In this capacity, she assisted the President of Valeant in the integration and management of multiple acquisitions, acted as the Secretary of the Specialty Pharmaceuticals Management Team, and led multiple special projects. Prior to this, Ms. Yankovich held positions at Novartis Vaccines and Diagnostics, Inc., Tufts Health Plan, and Boston Scientific. She holds a BS in Business Management from Bentley College, now Bentley University, where she graduated Cum Laude.